Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes

Elshaboury, Soha M.; Anderson, Joe R.
May 2013
Patient Preference & Adherence;2013, Vol. 7, p401
Academic Journal
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that is associated with severe functional impairment and a poor prognosis. Ambrisentan is a selective endothelin type A receptor antagonist approved for the treatment of patients with PAH World Health Organization group 1. The efficacy and safety of ambrisentan has been evaluated in the ARIES series (Ambrisentan for the Treatment of Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies), which has established its use as both monotherapy or in conjunction with other PAH therapies. Specifically, ambrisentan is effective at increasing exercise tolerance, decreasing the risk of functional class deterioration, and prolonging time to clinical worsening. Further, ambrisentan has a favorable effect on mortality, with an 88% patient survival rate after two years of therapy compared with a 61% survival rate as estimated by the National Institute of Health Registry. Ambrisentan is generally well tolerated in all patient groups, with the main side effects of peripheral edema, sinusitis, flushing, and nasal congestion considered to be mild to moderate in nature. Ambrisentan has several favorable qualities that potentially make it more acceptable to patients, including once-daily administration, limited adverse drug reactions and drug-drug interactions, and minimal risk of liver enzyme elevation. Because of the potential risk of teratogenicity associated with ambrisentan, it is only available through a limited distribution program, ie, LEAP (the Letairis Education and Access Program). Ongoing clinical trials will help to clarify the role of ambrisentan in the treatment of PAH.


Related Articles

  • Practice Patterns for Pulmonary Arterial Hypertension: A Survey of 741 Chest Physicians. Roberts, Micah J.; Helman, Donald // Hawaii Medical Journal;Sep2009, Vol. 68 Issue 8, p191 

    Introduction Current pulmonary arterial hypertension (PAH) guidelines recommend altering medical management when a patient "deteriorates or fails to respond." Due do a lack of published data, PAH guidelines do not specifically define failure or response. The purpose of our study was to...

  • Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension. Dandel, M.; Hetzer, R. // Current Vascular Pharmacology;Jun2003, Vol. 1 Issue 2, p171 

    Pulmonary arterial hypertension (PAH) is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the etiology of the increased vascular resistance. Prostacyclin treatment has markedly improved both the therapeutic options and...

  • TGF-β1/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts. Li Zhang; Yan Chen; Guixia Li; Minggang Chen; Wei Huang; Yanrui Liu; Yumei Li // Lipids in Health & Disease;1/5/2016, Vol. 15, p1 

    Background: Pulmonary adventitial fibroblasts (PAFs) are activated under stress stimuli leading to their differentiation into myofibroblasts, which is involved in vessel remodeling. 15-HETE is known as an important factor in vessel remodeling under hypoxia; however, the role of 15-HETE in PAF...

  • Electrocardiographic and Hemodynamic Correlations in Primary Pulmonary Hypertension. Kanemoto, Nariaki // Angiology;Sep1988, Vol. 39 Issue 9, p781 

    In order to evaluate the pulmonary hemodynamics in primary pulmonary hypertension, the relation between the standard 12-lead electrocardiogram (ECG) and pulmonary hemodynamics as determined by right-heart catheterization was analyzed. Significant positive correlations were noted between...

  • PRIMARY PULMONARY HYPERTENSION: FAMILIAL INCIDENCE. Boiteau, G. M.; Libanoff, A. J. // Angiology;May1963, Vol. 14 Issue 5, p260 

    The rare incidence of familial primary pulmonary hypertension (PPH) was presented in the case of two sister's. A brief review of the literature was presented. The congenital origin of PPH was discussed and related probably to the persistence of the fetal pulmonary circulation, or to the...

  • Preoperative Assessment and Management of Liver Transplant Candidates With Portopulmonary Hypertension. Cartin-Ceba, Rodrigo; Krowka, Michael J. // Advances in Pulmonary Hypertension;Summer2013, Vol. 12 Issue 2, p60 

    Pulmonary artery hypertension (PAH) that occurs as a consequence of portal hypertension is termed portopulmonary hypertension (POPH) and is associated with significant morbidity and mortality. Among liver transplant (LT) candidates, reported incidence rates of POPH range from 4.5% to 8.5%. The...

  • A friend to the airways: a review of the emerging clinical importance of the bronchial arterial circulation. Osiro, Stephen; Wear, Christopher; Hudson, Ryan; Ma, Xiao-Xiao; Zurada, Anna; Michalak, Maciej; Loukas, Marios // Surgical & Radiologic Anatomy;Nov2012, Vol. 34 Issue 9, p791 

    Lungs receive the bulk of their blood supply through the pulmonary arteries. The bronchial arteries, on the other hand, vascularize the bronchi and their surroundings. These two arteries anastomose near the alveolar ducts. Contrary to the pulmonary circulation which is fairly well studied, the...


    The article focuses on aneurysm of the splenic artery. The aneurysm is usually single, but there are cases of multiple sacs, up to ten in one patient. The size varies from 0.5 cm to 15 cm in diameter. One may also find multiple additional ancurysmata of various arteries of the body. Splenomegaly...

  • Alterations of Venous Drug Reactivity in Humans: Acquired and Genetic Factors. Vajo, Zoltan; Szekacs, Bela; Dachman, William // Angiology;May2000, Vol. 51 Issue 5, p361 

    Until recently, studies dealing with veins have almost always been the neglected part of vascular research. Recent data show an increasing rate of venous disease, and increasing evidence supports a role for veins in systemic diseases. The authors discuss and comment on findings of recent studies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics